The US Drug Supply Chain Security Act (DSCSA), enacted in 2013, set a ten-year path toward an electronic, interoperable system for tracing prescription drugs through the supply chain. The final phase — often called enhanced drug distribution security — introduced unit-level, serialised, electronic tracing. Because trading partners needed time to make the systems work together, the US Food and Drug Administration (FDA) provided phased stabilisation periods after the November 2024 milestone. This article is a neutral process explainer, not regulatory or legal advice.
What DSCSA set out to achieve
DSCSA’s goal is a supply chain in which prescription medicines can be traced electronically at the individual package level, so that suspect or illegitimate products can be identified, quarantined and investigated. The law applies to trading partners across the chain — manufacturers, repackagers, wholesale distributors and dispensers — and built up to its final state through a series of staged requirements over a decade. For the regulatory home of these rules, see our overview of the DSCSA.
Serialisation: the unique identifier
The foundation of enhanced traceability is serialisation. Each saleable unit of product carries a product identifier — a standardised code that, when applied at unit level, makes the package uniquely identifiable. A DSCSA product identifier typically combines four data elements:
- a standardised numerical identifier incorporating the product’s national drug code,
- a unique serial number,
- a lot number, and
- an expiration date.
These are encoded both in human-readable text and in a machine-readable two-dimensional data-matrix barcode, so the package can be scanned and verified electronically at each handoff. Serialisation is what makes unit-level tracing — as opposed to lot-level tracing — possible.
Interoperability: electronic and connected
The final phase requires that tracing be electronic and interoperable. In earlier phases, transaction information could pass between partners in mixed paper and electronic formats. Under enhanced security, the key data — transaction information and transaction statements — must move electronically and in a way that systems across different trading partners can exchange and reconcile. The three traditionally referenced data components are:
- Transaction information (TI): details of the product and the parties in a sale,
- Transaction history in earlier phases, and
- Transaction statement (TS): the seller’s attestation about the product’s legitimacy.
Interoperability is the hard part because it requires many independent companies’ systems to speak a common language reliably and at scale. That challenge is precisely why the FDA introduced stabilisation periods rather than demanding instant full compliance.
The stabilisation deadlines
Recognising that immediate, flawless interoperability across the whole industry was not realistic at the original 2023 milestone, the FDA exercised enforcement discretion to give trading partners more time to stabilise their systems. The result was a set of phased timelines extending past November 2024, with different categories of trading partner — large distributors, dispensers of different sizes, and others — given staggered periods to reach full interoperable exchange. The intent of stabilisation was continuity of supply: avoiding disruptions to patients’ access to medicines while the electronic systems matured.
The precise dates and partner categories are defined in FDA guidance, and trading partners track the specific timeline that applies to their role. The stabilisation approach is a transition mechanism, not a relaxation of the underlying requirements.
Who is affected and how roles differ
DSCSA applies across the chain, but obligations differ by role. Manufacturers and repackagers are responsible for applying the product identifier to packages and for responding to verification requests about identifiers they originated. Wholesale distributors handle large volumes and exchange transaction data with both upstream and downstream partners, making interoperable systems especially important to them. Dispensers — such as pharmacies — receive product and the associated electronic data, and have their own obligations around handling that information and managing suspect product. The staggered stabilisation timelines reflected these different roles and the differing readiness of each segment.
Because every link in the chain must exchange data with the next, the system only works if partners’ systems can communicate reliably. A single partner unable to send or receive the required electronic information can create friction for others, which is part of why the FDA prioritised continuity of supply during the transition.
How verification works in practice
Two everyday mechanisms illustrate the system. First, when a product identifier needs checking — for example, on a suspect product or a saleable return — partners can run a verification against the manufacturer’s records to confirm the identifier is valid. Second, the broader expectation is that suspect and illegitimate product handling is supported by the electronic data, so that questionable products can be quarantined and investigated using a traceable record.
For readers new to the terminology, our standards dictionary provides neutral definitions of related supply-chain and identifier concepts, and the explainer on persistent identifiers offers useful conceptual parallels to how serialised codes make objects uniquely findable.
Why the ten-year timeline mattered
It is worth remembering that DSCSA was deliberately phased over a decade. Earlier milestones introduced lot-level tracing, transaction documentation and authorised-trading-partner requirements, building the foundations on which unit-level serialised tracing could later sit. This staged design reflected the scale of the task: re-engineering how an entire national supply chain identifies, records and exchanges information about prescription medicines. The enhanced phase is the culmination of that build-up, and the stabilisation periods after November 2024 were a recognition that even a decade of preparation left genuine interoperability work to finish. Viewed across the full timeline, the move to electronic, interoperable, package-level tracing is the endpoint of a long, deliberate transition rather than a sudden change.
The bottom line
DSCSA’s enhanced phase replaces lot-level, partly paper-based tracing with serialised, electronic, interoperable tracing at the package level, supported by phased stabilisation so the industry could reach full interoperability without disrupting supply. Authoritative detail — including current timelines and guidance — is published by the FDA at fda.gov, which trading partners consult for binding requirements.